证券代码：002955 证券简称：鸿合科技 公告编号：2025-042 鸿合科技股份有限公司 关于实际控制人及其一致行动人、5%以上股东签署《股份转让 协议》与《表决权放弃协议》暨公司控制权拟发生变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 自身并代其作为普通合伙人暨执行事务合伙人的用于实际执行本次交易的主体，即 "瑞丞基金"）与鸿合科技股份有限公司（以下简称"公司"、"上市公司"或 "目标公司"）实际控制人XING XIUQING、邢正以及一致行动人鸿达成有限公司 （以下简称"鸿达成"）、持股5%以上股东王京和张树江正式签署《合肥瑞丞私募 基金管理有限公司与鸿达成有限公司及邢正、王京、张树江关于鸿合科技股份有限 公司之股份转让协议》（以下简称"《股份转让协议》"），瑞丞基金拟协议收购 鸿达成及邢正、王京、张树江合计持有的公司59,159,978股股份，占公司股份总数的 的用于实际执行本次交易的主体，即"瑞丞基金"）签署了《表决权放弃协议》， 张树江拟放弃剩余持有的公司17,860,872股股份（占公司股份总数的7.55%）对应的 表 ...

Core Viewpoint - The actual controller of Haimer Technology is planning to transfer control just over two years after taking over, indicating ongoing instability in the company's ownership and governance structure [1][4][10]. Group 1: Control Change Planning - Haimer Technology's actual controller, Su Zhancai, is planning a transfer of control and equity, with the new party expected to acquire at least 5% of the total shares and 22.39% of voting rights [4][5]. - This marks the third time since 2020 that Haimer Technology has planned a change in control, reflecting ongoing challenges in stabilizing ownership [6][10]. Group 2: Historical Context of Ownership Changes - In July 2020, the founder and major shareholder, Dou Jianwen, attempted to transfer 5% of shares to Gansu Guokai Investment Co., which would have changed the control of the company [6][8]. - The previous attempt to change control was terminated in April 2022 due to a lack of approval from the Gansu Provincial Government, highlighting regulatory challenges [7]. - In January 2023, Su Zhancai successfully took over control from Dou Jianwen, indicating a shift in ownership dynamics [8][9]. Group 3: Financial Performance - Haimer Technology's financial performance has been under pressure since 2020, with revenues of approximately 5.04 billion, 6.09 billion, 6.27 billion, and 7.44 billion from 2020 to 2023, respectively [11]. - The company reported net losses of approximately 5.98 billion, 2.62 billion in 2020 and 2021, but achieved small profits in 2022 and 2023 [11]. - However, in 2024, the company faced a significant loss again, with revenues around 6 billion and a net loss of approximately 2.28 billion [11]. Group 4: Industry Outlook - Despite challenges from the development of renewable energy, oil and gas resources are expected to remain crucial in global energy supply for the foreseeable future, especially in developing countries [12]. - The oil and gas equipment service industry is anticipated to achieve sustainable development through technological advancements that enhance production efficiency and reduce costs [12].

中国经济网北京6月10日讯 安奈儿(002875.SZ)今日复牌，收报16.08元，跌幅4.85%，总市值34.25亿元。 停牌前一个交易日，即5月30日，安奈儿涨停收报16.90元，涨幅10.03%。 本次权益变动后，新创源将成为公司的控股股东，黄涛将成为公司的实际控制人。 昨日晚间，安奈儿发布关于筹划公司控制权变更事项的进展暨复牌公告。此前公司收到控股股东、实际 控制人曹璋、王建青的通知，获悉其正在筹划公司控制权变更相关事项，曹璋和王建青拟通过向交易对 手方转让公司股份等方式，使交易对手方获得公司控制权。具体转让比例和实施方案尚待进一步沟通确 定。本次的交易对手方主要从事投资管理业务。若本次交易完成后，公司的控股股东、实际控制人将发 生变更。 财务数据显示，2020年安奈儿实现归属净利润约为-4681.59万元，自此之后公司业绩一直未能扭亏。 2021年至2024年，安奈儿实现归属净利润分别约为-302.95万元、-2.37亿元、-9955.15万元、-1.15亿元。 今年一季度，安奈儿实现归属于上市公司股东的净利润为-833.33万元。 鉴于上述事项尚存在重大不确定性，为保证公平信息披露，维护投资者利益 ...

胜帮英豪与中国生物签署《收购框架协议》后，中国生物将依据《收购框架协议》开展尽职调查工作， 尽职调查完成后，各方将确定是否签署协议，本次交易存在后续协议签署时间待定、未能签署及交易无 法达成的风险。另外，本次交易尚需取得深圳证券交易所的合规性确认意见并在中国证券登记结算有限 责任公司深圳分公司办理股份过户登记手续以及完成相关法律法规要求可能涉及的其他批准，该事项能 否最终实施完成及实施结果尚存在较大不确定性。 派林生物表示，本次公司控制权拟变更事项不会对公司的正常生产经营造成不利影响，不存在损害公司 及中小股东利益的情形。公司股票复牌后，公司将根据控制权变更事项的后续进展情况，严格按照法律 法规的有关规定及时履行信息披露义务。 （责任编辑：关婧） 中国经济网北京6月10日讯 今日，派林生物(000403.SZ)复牌，该股开盘即涨停报18.66元，涨幅 10.02%，随后打开涨停板，截至收盘报17.14元，涨幅1.06%。 派林生物昨日晚间披露关于筹划控制权变更事项进展暨复牌公告，公司控股股东胜帮英豪与中国生物技 术股份有限公司（以下简称"中国生物"）6月8日签署了《收购框架协议》，公司控股股东胜帮英豪拟将 所 ...

Group 1 - Anner plans to change its controlling shareholder to Shenzhen Xinchuangyuan Investment Partnership, with Huang Tao as the actual controller [2][5][7] - The share transfer agreement involves Cao Zhang and Wang Jianqing transferring 4.78% and 8.25% of their shares respectively to Xinchuangyuan at a price of 15.21 yuan per share, totaling 422 million yuan [5][7] - Following the transaction, Xinchuangyuan will hold 13.03% of Anner's shares and gain corresponding voting rights, while Cao Zhang will retain 14.35% of the shares but waive voting rights [7][8] Group 2 - Xinchuangyuan was established on May 27, with a registered capital of 395 million yuan, primarily engaged in investment management [8][9] - Huang Tao, the actual controller of Xinchuangyuan, is also the actual controller of Century Jinyuan Group, which has previously been involved in acquiring control of Wantu Technology [3][9] - Anner's stock price surged by 17.69% from May 28 to May 30, coinciding with the announcement of the change in control [13] Group 3 - Anner has been experiencing a decline in revenue, with a reported 20.70% decrease in revenue from 2023 to 2024, and a net loss of 114.66 million yuan in 2024 [14] - The company plans to adjust its store structure and enhance its online presence to develop a "super comfortable Anner" brand image over the next 3 to 5 years [15]

证券代码：002875 证券简称：安奈儿 公告编号：2025-030 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 奈儿，股票代码：002875）自 2025 年 6 月 10 日（星期二）开市起复牌。 广大投资者注意投资风险。 一、停牌事项 此前公司收到控股股东、实际控制人曹璋先生、王建青女士的通知，获悉其 正在筹划公司控制权变更相关事项，曹璋先生和王建青女士拟通过向交易对手方 转让公司股份等方式，使交易对手方获得公司控制权。具体转让比例和实施方案 尚待进一步沟通确定。本次的交易对手方主要从事投资管理业务。若本次交易完 成后，公司的控股股东、实际控制人将发生变更。 鉴于上述事项尚存在重大不确定性，为保证公平信息披露，维护投资者利益， 避免造成公司股价异常波动，根据《深圳证券交易所股票上市规则》《深圳证券 交易所上市公司自律监管指引第 6 号——停复牌》等有关规定，经公司向深圳证 券交易所申请，公司股票（股票简称：安奈儿，股票代码：002875）自 2025 年 年 6 月 5 日刊登在《证券时报》《中国证券报》及巨潮资讯网 深圳市安奈儿股份有限 ...

安奈儿(002875.SZ)公告称，公司控股股东、实际控制人曹璋、王建青与深圳新创源投资合伙企业（有 限合伙）签署了《股份转让协议》，拟通过转让公司股份的方式，使新创源获得公司控制权。公司股票 将于2025年6月10日开市起 复牌。本次交易事项尚需经尽职调查、交易所合规性审核及办理股份协议转 让过户相关手续，存在重大不确定性。 ...

Overview of the Transaction - The controlling shareholder of the company, Pailin Biopharmaceutical Co., Ltd., is set to change from Shengbang Yinghao Investment Partnership to China National Pharmaceutical Group Co., Ltd. [1][8] - Shengbang Yinghao holds 21.03% of the company's shares, all of which are tradable shares [2][8]. Parties Involved - The transferor is Shengbang Yinghao Investment Partnership, located in Jiangxi Province, with a capital contribution of 500 million yuan [2][5]. - The transferee is China National Pharmaceutical Group Co., Ltd., based in Beijing, with a registered capital of approximately 980.82 million yuan [2][5]. Key Terms of the Agreement - The acquisition framework agreement was signed on June 8, 2025, with a transfer price of approximately 384.38 million yuan, plus interest calculated at an annual rate of 9% from March 20, 2023, until the formal transaction documents are signed [5][6]. - The agreement stipulates that the number of shares may be adjusted in case of corporate actions like stock splits or dividends [5]. Due Diligence and Compliance - The agreement is contingent upon the completion of due diligence by the transferee, and the final transaction amount will be determined in the formal share transfer agreement [6][9]. - The transaction requires compliance confirmation from the Shenzhen Stock Exchange and other regulatory approvals [9]. Impact on the Company - The transaction is not expected to adversely affect the company's normal operations or the interests of minority shareholders [8][9]. - The transaction does not constitute a tender offer or related party transaction [8].

Core Viewpoint - The announcement of a potential change in control at Zhongying Electronics raises uncertainties regarding its future strategic direction and leadership, particularly with the possible departure of founder Fu Qiming, who has significantly influenced the company's growth and market positioning in the integrated circuit design sector [1][8]. Group 1: Company Overview - Zhongying Electronics specializes in integrated circuit design, operating under a fabless model, focusing on chip design, research, and sales [4]. - As of 2024, the company reported a revenue of 1.343 billion yuan, reflecting a slight year-on-year increase of 3.32%, indicating its competitive market position despite a challenging environment [4]. - The net profit attributable to shareholders was 134 million yuan, showing a decrease due to a one-time compensation received in the previous reporting period, suggesting a more favorable profit trend when excluding this non-recurring item [4]. Group 2: Product Performance - From 2022 to 2024, the total sales volume of chips increased steadily from 713 million to 885 million units, marking a nearly 9% year-on-year growth in 2024, indicating rising market demand [5]. - The company's gross margin was reported at 33.60%, down 2.01% year-on-year, primarily due to intense market competition and price reductions [5]. Group 3: Product Structure and Market Position - Zhongying Electronics' main products include industrial MCUs, battery management chips, and AMOLED display driver chips, with a strong market share in the industrial MCU sector, particularly in household appliances [6]. - The company has developed several 32-bit Cortex M0+ products for the home appliance market and is expanding its overseas market presence, including new clients in Europe and Japan [6][7]. Group 4: Research and Development - In 2024, the company invested 300 million yuan in R&D, accounting for 22.35% of its revenue, although this figure has seen a slight decline over three consecutive years [7]. - Zhongying Electronics holds a total of 135 valid patents, with 133 being invention patents, showcasing its commitment to innovation and technological advancement [7]. Group 5: Leadership and Strategic Implications - The potential change in control involving Weilang International could lead to significant strategic adjustments for Zhongying Electronics, especially if Fu Qiming exits the decision-making team [8]. - The future trajectory of the company remains uncertain, with the possibility of either leveraging new shareholder support for growth or facing challenges during the transition [8].

Group 1 - The company, Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd., experienced abnormal stock trading fluctuations on June 5 and June 6, 2025, as per the relevant regulations [1] - The board of directors confirmed that there are no undisclosed significant matters affecting the company's stock price, apart from the disclosed share transfer agreement with Beijing Fuhai, which involves the acquisition of 43,855,883 shares from the controlling shareholder Gao Fan [1][2] - The company has disclosed the necessary documents regarding the change of control, including a brief and detailed report on equity changes, and has confirmed that there are no other undisclosed matters that could impact the stock price [2] Group 2 - The company will continue to comply with legal and regulatory requirements for information disclosure and will ensure timely updates regarding any significant changes [2] - The completion of the equity change is subject to compliance confirmation from the Shenzhen Stock Exchange and other necessary approvals, indicating potential uncertainties in the implementation of the transaction [2]